vs
First Bancorp, Inc（FNLC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是First Bancorp, Inc的1.4倍（$35.5M vs $25.8M），First Bancorp, Inc净利率更高（39.4% vs -304.2%，领先343.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 17.5%），First Bancorp, Inc自由现金流更多（$34.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 18.1%）
第一银行公司（First Bancorp, Inc）是一家银行控股公司，其核心业务通过总部位于康涅狄格州斯坦福的爱国者国家银行（Patriot Bank NA）开展，相关 banking 业务也以PNBK代码在纳斯达克挂牌交易。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FNLC vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.8M | $35.5M |
| 净利润 | $10.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 48.1% | -304.8% |
| 净利率 | 39.4% | -304.2% |
| 营收同比 | 17.5% | 681.7% |
| 净利润同比 | 39.7% | 39.6% |
| 每股收益（稀释后） | $0.91 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $25.8M | $35.5M | ||
| Q3 25 | $24.5M | $5.2M | ||
| Q2 25 | $22.5M | $19.2M | ||
| Q1 25 | $21.8M | $14.7M | ||
| Q4 24 | $22.0M | $4.5M | ||
| Q3 24 | $20.5M | $26.1M | ||
| Q2 24 | $19.2M | $14.4M | ||
| Q1 24 | $18.5M | $13.8M |
| Q4 25 | $10.2M | $-108.1M | ||
| Q3 25 | $9.1M | $-162.3M | ||
| Q2 25 | $8.1M | $-171.9M | ||
| Q1 25 | $7.1M | $-202.5M | ||
| Q4 24 | $7.3M | $-178.9M | ||
| Q3 24 | $7.6M | $-95.8M | ||
| Q2 24 | $6.2M | $-97.5M | ||
| Q1 24 | $6.0M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 48.1% | -304.8% | ||
| Q3 25 | 45.2% | -3327.6% | ||
| Q2 25 | 43.7% | -916.8% | ||
| Q1 25 | 39.3% | -1297.9% | ||
| Q4 24 | 39.5% | -4042.4% | ||
| Q3 24 | 44.6% | -377.1% | ||
| Q2 24 | 38.8% | -697.4% | ||
| Q1 24 | 39.3% | -698.4% |
| Q4 25 | 39.4% | -304.2% | ||
| Q3 25 | 37.0% | -3135.3% | ||
| Q2 25 | 35.8% | -894.2% | ||
| Q1 25 | 32.5% | -1373.3% | ||
| Q4 24 | 33.1% | -3935.5% | ||
| Q3 24 | 36.9% | -367.5% | ||
| Q2 24 | 32.1% | -676.6% | ||
| Q1 24 | 32.5% | -662.4% |
| Q4 25 | $0.91 | $-0.17 | ||
| Q3 25 | $0.81 | $-0.36 | ||
| Q2 25 | $0.72 | $-0.41 | ||
| Q1 25 | $0.63 | $-0.50 | ||
| Q4 24 | $0.66 | $-0.56 | ||
| Q3 24 | $0.68 | $-0.34 | ||
| Q2 24 | $0.55 | $-0.40 | ||
| Q1 24 | $0.54 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $95.5M | $9.6M |
| 股东权益账面价值 | $283.1M | $1.1B |
| 总资产 | $3.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
| Q4 25 | $95.5M | $9.6M | ||
| Q3 25 | $95.5M | $11.9M | ||
| Q2 25 | $95.0M | $14.2M | ||
| Q1 25 | $70.0M | $16.4M | ||
| Q4 24 | $95.0M | $19.0M | ||
| Q3 24 | $95.0M | $20.5M | ||
| Q2 24 | $70.0M | $22.9M | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $1.1B | ||
| Q3 25 | $274.6M | $1.0B | ||
| Q2 25 | $265.5M | $919.1M | ||
| Q1 25 | $259.7M | $933.9M | ||
| Q4 24 | $252.5M | $1.0B | ||
| Q3 24 | $256.8M | $524.6M | ||
| Q2 24 | $244.7M | $584.4M | ||
| Q1 24 | $242.6M | $401.2M |
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.2B | $1.4B | ||
| Q2 25 | $3.2B | $1.3B | ||
| Q1 25 | $3.2B | $1.3B | ||
| Q4 24 | $3.2B | $1.4B | ||
| Q3 24 | $3.1B | $726.5M | ||
| Q2 24 | $3.1B | $775.9M | ||
| Q1 24 | $3.0B | $557.8M |
| Q4 25 | 0.34× | 0.01× | ||
| Q3 25 | 0.35× | 0.01× | ||
| Q2 25 | 0.36× | 0.02× | ||
| Q1 25 | 0.27× | 0.02× | ||
| Q4 24 | 0.38× | 0.02× | ||
| Q3 24 | 0.37× | 0.04× | ||
| Q2 24 | 0.29× | 0.04× | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $37.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | 133.9% | -133.1% |
| 资本支出强度资本支出/营收 | 12.5% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $55.3M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $37.8M | $-46.1M | ||
| Q3 25 | $12.9M | $-117.4M | ||
| Q2 25 | $7.4M | $-76.4M | ||
| Q1 25 | $2.2M | $-132.0M | ||
| Q4 24 | $26.0M | $-115.4M | ||
| Q3 24 | $9.8M | $-59.2M | ||
| Q2 24 | $6.4M | $-82.2M | ||
| Q1 24 | $-1.5M | $-102.3M |
| Q4 25 | $34.6M | $-47.3M | ||
| Q3 25 | $12.6M | $-117.6M | ||
| Q2 25 | $7.2M | $-79.6M | ||
| Q1 25 | $828.0K | $-133.8M | ||
| Q4 24 | $24.6M | $-116.7M | ||
| Q3 24 | $9.6M | $-63.8M | ||
| Q2 24 | $6.3M | $-83.4M | ||
| Q1 24 | $-1.8M | $-109.0M |
| Q4 25 | 133.9% | -133.1% | ||
| Q3 25 | 51.4% | -2272.5% | ||
| Q2 25 | 32.1% | -413.9% | ||
| Q1 25 | 3.8% | -907.4% | ||
| Q4 24 | 111.7% | -2567.7% | ||
| Q3 24 | 47.0% | -244.6% | ||
| Q2 24 | 32.9% | -578.5% | ||
| Q1 24 | -9.8% | -789.9% |
| Q4 25 | 12.5% | 3.5% | ||
| Q3 25 | 1.2% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 6.2% | 12.4% | ||
| Q4 24 | 6.7% | 28.6% | ||
| Q3 24 | 0.5% | 17.5% | ||
| Q2 24 | 0.3% | 8.2% | ||
| Q1 24 | 1.8% | 48.2% |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
